SciVision Biotech Inc. (1786.TW)
TWD 96.3
(-0.82%)
TWD 96.3
(-0.82%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -163.18 Million TWD | 4.55% |
| 2022 | -170.96 Million TWD | -626.04% |
| 2021 | -23.54 Million TWD | 68.04% |
| 2020 | -73.68 Million TWD | -315.4% |
| 2019 | -17.73 Million TWD | -125.72% |
| 2018 | 68.95 Million TWD | -59.53% |
| 2017 | 170.4 Million TWD | 898.46% |
| 2016 | -21.34 Million TWD | 87.75% |
| 2015 | -174.27 Million TWD | 52.31% |
| 2014 | -365.41 Million TWD | 44.8% |
| 2013 | -662.01 Million TWD | -490.24% |
| 2012 | -112.16 Million TWD | -44.63% |
| 2011 | -77.55 Million TWD | -680.66% |
| 2010 | -9.93 Million TWD | -127.14% |
| 2009 | 36.6 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -231.94 Million TWD | -42.13% |
| 2024 Q2 | -381.79 Million TWD | -64.61% |
| 2023 Q4 | -163.18 Million TWD | 48.12% |
| 2023 Q3 | -314.55 Million TWD | -1.06% |
| 2023 FY | -163.18 Million TWD | 4.55% |
| 2023 Q1 | -215.35 Million TWD | -25.96% |
| 2023 Q2 | -311.25 Million TWD | -44.53% |
| 2022 FY | -170.96 Million TWD | -626.04% |
| 2022 Q4 | -170.96 Million TWD | 66.37% |
| 2022 Q3 | -508.42 Million TWD | -659.87% |
| 2022 Q2 | -66.91 Million TWD | 24.99% |
| 2022 Q1 | -89.19 Million TWD | -278.78% |
| 2021 FY | -23.54 Million TWD | 68.04% |
| 2021 Q2 | 20.65 Million TWD | -67.03% |
| 2021 Q4 | -23.54 Million TWD | 48.04% |
| 2021 Q1 | 62.65 Million TWD | 185.03% |
| 2021 Q3 | -45.32 Million TWD | -319.39% |
| 2020 Q3 | -38.61 Million TWD | -239.48% |
| 2020 FY | -73.68 Million TWD | -315.4% |
| 2020 Q4 | -73.68 Million TWD | -90.82% |
| 2020 Q1 | 92.7 Million TWD | 622.65% |
| 2020 Q2 | 27.68 Million TWD | -70.14% |
| 2019 Q4 | -17.73 Million TWD | -120.14% |
| 2019 Q1 | -183.37 Million TWD | -365.94% |
| 2019 FY | -17.73 Million TWD | -125.72% |
| 2019 Q3 | 88.05 Million TWD | 379.94% |
| 2019 Q2 | -31.45 Million TWD | 82.85% |
| 2018 Q2 | 103.42 Million TWD | 1.45% |
| 2018 Q1 | 101.94 Million TWD | -40.17% |
| 2018 FY | 68.95 Million TWD | -59.53% |
| 2018 Q4 | 68.95 Million TWD | 236.48% |
| 2018 Q3 | 20.49 Million TWD | -80.19% |
| 2017 Q1 | 50.96 Million TWD | 338.79% |
| 2017 Q3 | 95.44 Million TWD | 60.66% |
| 2017 Q4 | 170.4 Million TWD | 78.53% |
| 2017 FY | 170.4 Million TWD | 898.46% |
| 2017 Q2 | 59.41 Million TWD | 16.58% |
| 2016 Q2 | -16.16 Million TWD | 90.43% |
| 2016 Q1 | -168.8 Million TWD | 3.14% |
| 2016 FY | -21.34 Million TWD | 87.75% |
| 2016 Q3 | 79.61 Million TWD | 592.63% |
| 2016 Q4 | -21.34 Million TWD | -126.8% |
| 2015 Q4 | -174.27 Million TWD | 20.26% |
| 2015 FY | -174.27 Million TWD | 52.31% |
| 2015 Q3 | -218.56 Million TWD | 9.82% |
| 2015 Q2 | -242.35 Million TWD | 16.25% |
| 2015 Q1 | -289.36 Million TWD | 20.81% |
| 2014 Q3 | -266.73 Million TWD | 11.27% |
| 2014 Q2 | -300.6 Million TWD | -6.7% |
| 2014 Q1 | -281.72 Million TWD | 57.44% |
| 2014 FY | -365.41 Million TWD | 44.8% |
| 2014 Q4 | -365.41 Million TWD | -36.99% |
| 2013 Q4 | -662.01 Million TWD | -1129.4% |
| 2013 Q1 | -67.98 Million TWD | 39.38% |
| 2013 FY | -662.01 Million TWD | -490.24% |
| 2013 Q3 | -53.84 Million TWD | 29.02% |
| 2013 Q2 | -75.86 Million TWD | -11.59% |
| 2012 FY | -112.16 Million TWD | -44.63% |
| 2012 Q3 | -97.98 Million TWD | -0.38% |
| 2012 Q2 | -97.61 Million TWD | 0.0% |
| 2012 Q4 | -112.16 Million TWD | -14.47% |
| 2011 Q4 | -77.55 Million TWD | 0.0% |
| 2011 Q2 | -53.31 Million TWD | 0.0% |
| 2011 FY | -77.55 Million TWD | -680.66% |
| 2010 Q4 | -9.93 Million TWD | 0.0% |
| 2010 FY | -9.93 Million TWD | -127.14% |
| 2009 FY | 36.6 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 227.48 Million TWD | 171.735% |
| Maxigen Biotech Inc. | -431.03 Million TWD | 62.14% |
| Bionime Corporation | 2.42 Billion TWD | 106.728% |
| Pegavision Corporation | 63.52 Million TWD | 356.896% |
| Visco Vision Inc. | 563 Million TWD | 128.985% |